By Annabella PultzNielsen COPENHAGEN (Reuters) – Novo Nordisk's long-serving chief executive Lars Rebien Sorensen is to step down early, it was announced on Thursday, at a time when the world's largest insulin maker has said it faces increased competition in the U.S. market where it generates about half its revenues. The company said Rebien Sorensen will be succeeded from January by Lars Fruergaard Jorgensen, currently executive vice president and head of corporate development. In a further management change announced on Thursday Jacob Riis becomes head of the North American business.
Here is the original post:
Novo Nordisk’s veteran CEO Lars Rebien Sorensen to step down
